Biological response modifiers may yield a new class of drugs to treat arthritis.
Skolnick
A A
AA
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D018121:Receptors, Cytokine / Q000187:drug effects*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D018121:Receptors, Cytokine; D011993:Recombinant Fusion Proteins